Cytek Biosciences (CTKB) Stock Statistics & Valuation Metrics

Cytek Biosciences has a market cap or net worth of $514.20M. The enterprise value is $456.37M.

Cytek Biosciences has 128,550,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytek Biosciences’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -10.21%.

The current PE Ratio of Cytek Biosciences is ―. Cytek Biosciences’s PEG ratio is -0.00941.

In the last 12 months, Cytek Biosciences had revenue of 201.49M and earned -66.54M in profits. Earnings per share was -0.52.

In the last 12 months, operating cash flow was -4.69M and capital expenditures -4.08M, giving a free cash flow of -8.77M billion.

Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Cytek Biosciences upcoming earnings date is May 13, 2026, After Close (Confirmed).

Cytek Biosciences as a current ratio of 5.04, with Debt / Equity ratio of 9.66%

In the past 12 months, Cytek Biosciences has paid 36.70M in taxes.

Cytek Biosciences EV to EBITDA ratio is -33.77, with an EV/FCF ratio of -66.97.

Cytek Biosciences has $261.53M in cash and marketable securities with $33.02M in debt, giving a net cash position of $228.50M billion.

Gross margin is 51.84%, with operating margin of -20.04%, and net profit margin of -33.02%.

The average price target for Cytek Biosciences is $6.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy